Asset Management One Co. Ltd. Has $11.70 Million Stake in United Therapeutics Corporation $UTHR

Asset Management One Co. Ltd. decreased its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 5.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,267 shares of the biotechnology company’s stock after selling 1,243 shares during the period. Asset Management One Co. Ltd. owned about 0.05% of United Therapeutics worth $11,698,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Geneos Wealth Management Inc. boosted its stake in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 70 shares during the last quarter. Jump Financial LLC bought a new position in United Therapeutics in the 2nd quarter valued at $277,000. Cerity Partners LLC grew its stake in United Therapeutics by 77.3% in the 2nd quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares during the period. Finally, Bank of Nova Scotia increased its position in shares of United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Royal Bank Of Canada increased their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Wells Fargo & Company boosted their target price on shares of United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. HC Wainwright increased their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. TD Cowen raised their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. Finally, Raymond James Financial began coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $601.50.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Company-reported clinical data to be presented at ISHLT (ARTISAN and PHINDER interim analyses) suggest earlier detection/management benefits in pulmonary hypertension, right-ventricular improvement with high‑dose treprostinil, and broader pipeline visibility including lung donor expansion and xenotransplantation — these findings can support longer-term revenue and pipeline value. United Therapeutics Presents New Data at ISHLT 2026
• Positive Sentiment: Analyst consensus remains constructive — UTHR carries an average recommendation of “Moderate Buy,” which can underpin investor confidence and valuation support amid near-term volatility. United Therapeutics Given Average Recommendation of Moderate Buy
• Neutral Sentiment: A comparative valuation piece (CPRX vs UTHR) discusses which is a better value — useful context for value-oriented investors but not company-specific news likely to move the stock materially on its own. CPRX or UTHR: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Unusually large options trading was reported, indicating elevated short-term interest or hedging activity — this can amplify intraday moves but is ambiguous on direction. United Therapeutics Target of Unusually Large Options Trading
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares (~$5.57M) on April 17 and reduced her stake by ~19% in that filing — large insider sales often trigger investor concern about near-term outlook or personal liquidity needs. SEC Filing – CEO Insider Sale
• Negative Sentiment: Additional recent insider sales reported: CFO sale totaling about $5.77M and a director sale of ~$578.9k — multiple senior-level sales in close succession increase perceived selling pressure. CFO Insider Sale Director Insider Sale
• Negative Sentiment: Earlier small CEO sale (~$40k) was also disclosed — while smaller, it adds to the sequence of insider disposals that investors are noting. CEO Insider Sale (smaller)

Insider Transactions at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $576.82, for a total value of $4,787,606.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $26,056,113.04. The trade was a 15.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $577.18, for a total transaction of $5,771,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,894,849.68. This represents a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 401,295 shares of company stock worth $212,743,596. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Stock Down 2.5%

Shares of UTHR opened at $573.44 on Tuesday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $607.89. The stock has a market cap of $25.13 billion, a PE ratio of 20.55, a P/E/G ratio of 1.68 and a beta of 0.75. The business’s 50-day moving average price is $528.74 and its 200-day moving average price is $491.26.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm’s revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the business posted $6.19 earnings per share. Analysts expect that United Therapeutics Corporation will post 27.93 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.